Sanuwave Health Reports Record Q2 Revenue Growth

SANUWAVE Health Inc. ( (SNWV) ) has released its Q2 earnings. Here is a breakdown of the information SANUWAVE Health Inc. presented to its investors.

Sanuwave Health, Inc., a company specializing in FDA-approved wound care products, has reported its financial results for the second quarter of fiscal year 2025. The company, which focuses on non-invasive medical systems for tissue repair and regeneration, operates primarily in the healthcare sector.

In the latest earnings report, Sanuwave Health announced a significant increase in revenue, reaching $10.2 million for Q2 2025, marking a 42% rise compared to the same quarter in the previous year. This revenue growth represents the highest Q2 quarterly revenues in the company’s history.

Key financial highlights include a gross margin improvement to 78.3% from 73.2% in Q2 2024, and an adjusted EBITDA of $3.4 million, up from $1.5 million in the previous year. Operating income slightly decreased to $1.9 million due to equity compensation costs, while net income was $1.1 million, down from $6.6 million in Q2 2024, which had benefited from a one-time gain on debt extinguishment.

Looking ahead, Sanuwave Health is optimistic about its future performance, forecasting Q3 2025 revenues between $12 million and $12.7 million. The company aims to build momentum with new sales and marketing strategies, setting the stage for potential breakout performance in Q4 2025 and beyond.